Skip to main content
NIH funding notice PAR-20-288

NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)

Closed on January 4, 2021.

Posted
August 26, 2020
Close date
January 4, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,020,312 in first-year total cost, median $162,120.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 SRB-1 (A1)]10

Most frequent institutions

  1. BECKMAN RESEARCH INSTITUTE/CITY OF HOPE2
  2. COLD SPRING HARBOR LABORATORY1
  3. DANA-FARBER CANCER INST1
  4. EMORY UNIVERSITY1
  5. JOHNS HOPKINS UNIVERSITY1
Competing awards under PAR-20-288 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Functional Analysis of Structure Specific Nucleases in Genome Stability and Cancers2R50CA211397-06ZHENG, LIBECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA$377,434ZCA1
2021Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer2R50CA211399-06BIRD, GREGORY HOWARDDANA-FARBER CANCER INST, MA$332,082ZCA1
2021Preclinical Models for Cancer Therapeutic Development2R50CA211506-06PARK, YOUNGKYUCOLD SPRING HARBOR LABORATORY, NY$248,045ZCA1
2021BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIES2R50CA211466-06RETTIG, MICHAELWASHINGTON UNIVERSITY, MO$247,925ZCA1
2021Identifying and exploiting metabolic vulnerabilities in cancer using mass spectrometry and tracing approaches1R50CA252146-01A1CORDES, THEKLAUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$168,344ZCA1
2021Definition and perturbation of cell-regulatory heterogeneities in solid tumors1R50CA265089-01WANG, LIXINUNIVERSITY OF VIRGINIA, VA$155,896ZCA1
2021Deconstructing cellular heterogeneity and subpopulation cooperation in non-small cell lung cancer metastasis1R50CA265345-01MOUW, JANNA KEMORY UNIVERSITY, GA$143,985ZCA1
2021Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)1R50CA265307-01NILSSON, MONIQUE BUNIVERSITY OF TX MD ANDERSON CAN CTR, TX$140,341ZCA1
2021Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions1R50CA252135-01A1CASERTA, ENRICOBECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA$112,893ZCA1
2021INTEGRATING MOLECULAR BIOLOGY WITH CANCER MOLECULAR IMAGING AND THERANOSTICS1R50CA243562-01A1KRISHNAMACHARY, BALAJIJOHNS HOPKINS UNIVERSITY, MD$93,367ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-20-288: NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) | ScienceDex | ConductScience